Slingshot Insights | Janssen Overview

JANSSEN Overview

Upcoming Projects (JANSSEN)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (JANSSEN)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (JANSSEN)

Genmab Achieves USD 30 Million Milestone in DARZALEX (daratumumab) Collaboration with Janssen
Tickers: JANSSEN, GE9.F
Occurred on: May 30, 2016
FDA Expands Indication of INVOKAMET (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
Ticker: JANSSEN
Occurred on: May 24, 2016
New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease
Ticker: JANSSEN
Occurred on: May 23, 2016

Strategic Initiatives (JANSSEN)

Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended release tablets and NUCYNTA (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
Tickers: DEPO, Janssen
Announcement Date: Apr 02, 2015